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Abstract: Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody 
that was recently approved for the treatment of patients with rheumatoid arthritis, psoriatic arthri-
tis, and ankylosing spondylitis. This review covers the published clinical trial data on the use of 
golimumab for the approved indications mentioned above with respect to efficacy and safety. 
The various ongoing trials for golimumab have yielded promising results in terms of efficacy 
and safety in methotrexate-naive and -resistant patients with rheumatoid arthritis, as well as in 
patients who were previously treated with other anti-TNF agents. In addition, the efficacy of 
golimumab in psoriatic arthritis and ankylosing spondylitis has also been demonstrated. The real 
safety information will be available only once the drug has been used in many more patients, 
who frequently have comorbid conditions.
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Introduction
Advances in the treatment of rheumatic diseases have been achieved from an improved 
understanding of the pathogenesis of these diseases and biotechnological advances 
that have allowed targeted approaches to the pathological processes.
Tumor necrosis factor (TNF)-α has an important role in inflammatory processes 
in rheumatoid arthritis (RA) and in other immune-mediated disorders. Consequently, 
TNF-α has emerged as an important target for the development of therapeutic   strategies 
for treating not only RA but also other inflammatory arthritides as well.1
RA usually affects hands and feet; psoriatic arthritis (PsA) can affect both 
peripheral joints and the spine, whereas ankylosing spondylitis (AS) affects the spine 
predominately. The worldwide prevalence of these conditions is approximately 2% 
in the adult population.2–4 Although they are unique conditions, these inflammatory 
joint diseases share many clinical features and treatment strategies, which have led to 
the development of agents that target common pathways among the diseases. Since 
their introduction, the TNF-α inhibitors have become firmly established as effective 
treatments for several rheumatologic diseases, including RA, AS, and PsA, either 
alone or in combination with traditional, nonbiologic disease-modifying antirheumatic 
drugs (DMARDs).5–7
Despite the benefits that these biologic agents have brought since entering the 
treatment paradigm of these entities, not all patients respond adequately to them and 
some patients may lose their response over time. Interestingly, the strategy of   switching 
patients who no longer respond to one of the TNF-α blockers to another has often Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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turned out to be effective.8,9 This insufficient response with 
current therapy along with the data indicating that switching 
among the available TNF antagonists is safe and effective has, 
therefore, led to the development of new TNF-α inhibitors.
Currently available anti-TNF agents include infliximab, 
adalimumab, etanercept, certolizumab, and golimumab 
(GM). GM (SimponiTM; Centocor), alone or in combination 
with MTX, was approved by the US Food and Drug Adminis-
tration on April, 2009 for the treatment of moderate to severe 
RA, active PsA (alone or with MTX), and active AS.
This review will summarize current evidence covering 
the pharmacology, efficacy, and safety of GM in RA, AS, 
and PsA.
Pharmacology and pharmacokinetics
GM, also known as CNTO-148, is a human   immunoglobulin 
G1-κ monoclonal antibody that is specific for TNF-α, which 
binds to both the soluble and transmembrane forms of human 
TNF-α. Being a fully human monoclonal antibody, GM resem-
bles adalimumab, which was the first such product to reach the 
market. However, amino acid sequences of the light and heavy 
chains of GM are identical to those of infliximab.1
The pharmacokinetics of GM have been studied mainly 
in a trial conducted by Zhou et al,10 whereas several 
phase 2 and 3 trials in different patient populations provided 
  additional pharmacokinetic data.11–14 GM appears to exhibit 
  dose-dependent pharmacokinetics with both intravenous 
(IV) and subcutaneous (SC) administration; steady-state 
concentration is reached within 12 weeks. With SC admin-
istration, the time to reach maximum serum concentra-
tion (2.5 mcg/mL) in healthy participants ranges from 
2 to 6 days. Concomitant use of MTX results in a mean 
steady-state trough serum concentration of 0.4–0.6 mcg/mL, 
0.5 mcg/mL, and 0.8 mcg/mL in patients with RA, PsA, 
and AS, respectively. Patients with RA, PsA, and AS who 
were treated with GM and MTX had approximately 52%, 
36%, and 21% higher mean steady-state trough concentra-
tions compared with those treated without concomitant 
MTX, suggesting a potential drug interaction between 
these 2 agents. The median half-life appeared to increase 
with an increase in dose, with a median of 6.6 days for 
0.1 mg/kg and 19.3 days for 10 mg/kg of GM. Based on 
population pharmacokinetic models, for a patient weigh-
ing 70 kg, mean apparent clearance was 1.38–1.91 L/d and 
apparent volume of distribution was 22.6–26.7 L. Popula-
tion pharmacokinetic analysis in patients with RA also 
indicated that concomitant use of MTX could reduce the 
apparent clearance of GM by 17.1%.
Efficacy
RA
Phase 2 study
GM was investigated in a phase 2, randomized,   double-blind, 
placebo-controlled, dose-ranging study consisting of 
172 patients with active RA with an inadequate response 
to methotrexate (MTX).11 All eligible patients had 
been unsuccessfully treated with MTX for at least 
3 months ($10 mg/wk) and had $6 swollen, $6 tender 
joints, and at least 2 of the following: C-reactive protein 
(CRP) level $1.5 mg/dL, erythrocyte sedimentation rate 
(ESR) $28 mm/h, and morning stiffness of $30 minutes. 
Patients who were on stable doses of nonsteroidal 
anti-  inflammatory drugs (NSAIDs) and corticosteroids 
(#10 mg/d of prednisone) were allowed to continue their 
use during the study. Patients were assigned to one of 
5   treatment groups: placebo, GM 50 or 100 mg SC every 2 or 
4 weeks. All patients continued to receive stable doses of 
MTX through the end of the study.
To assess GMs efficacy, the primary end point was estab-
lished as the percentage of individuals fulfilling the American 
College of Rheumatology (ACR20) criteria after 16 weeks.15 
Secondary end points included the change from baseline in 
the disease activity score in 28 joints (DAS28) at week 16, 
numeric index of ACR response (ACR-N), and ACR20/50/70 
responses over time through week 52.15–17
The demographics and baseline clinical characteristics 
were similar to those in the usual RA clinical trials, with a 
median age of 53.5 years and median duration of disease 
7.8 years (Table 1). In all, 87.6% and 82.9% of patients 
randomized to combined GM plus MTX groups and placebo 
plus MTX, respectively, completed 16 weeks of study. The 
discontinuation rates in the individual GM plus MTX dose 
groups did not vary in a dose-dependent manner.
The study met its primary end point at week 16; the 
ACR20 response of patients in the combined GM plus MTX 
group was 61.3% vs 37.1% in patients treated with placebo 
plus MTX (P = 0.01) (Table 2). When compared individually 
with the placebo group, only the highest dose group (100 mg 
GM every 2 weeks) showed a significant difference in the 
proportion of patients achieving an ACR20 response (79.4%; 
P , 0.001 compared with placebo).
The secondary end points of ACR50/70 responses, 
improvement in DAS28, and ACR-N at week 16 were also 
significantly improved in the combined GM plus MTX groups 
as compared with placebo plus MTX (Table 2). Correlated 
with the favorable clinical outcomes, 26.3% of patients 
in the combined GM groups achieved remission (DAS28 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Results from randomized controlled trials of golimumab in rheumatoid arthritis
Reference Duration Treatment ACR20 
(%)
ACR50 
(%)
ACR70  
(%)
DAS28-CRP 
remission (%)
Kay et al11 16 wk Placebo + MTX 37.1 5.7 0.0 5.7
GM 50 mg  
q4 wk + MTX
60 37.1* 8.6 20
GM 50 mg  
q2 wk + MTX
50 23.5* 14.7* 26.5*
GM 100 mg 
q4 wk + MTX
55.9 29.4* 17.6* 32.4*
GM 100 mg q2 wk + MTX 79.4* 32.4* 8.8 26.5*
GM combined +	
MTX
61.3* 30.7* 12.4* 26.3*
Keystone et al18 
GO-FORwARD
24 wk 14 wk results
Placebo + MTX 33.1 9.8 3.8 NR
GM 100 mg q4 
wk + placebo
44.4 20.3* 7.5 NR
GM 50 mg  
q4 wk + MTX
55.1* 34.8* 13.5* NR
GM 100 mg  
q4 wk + MTX
56.2* 29.2* 9.0 NR
24 wk results
Placebo + MTX 27.8 13.5 5.3 NR
GM 100 mg 
q4 wk + placebo
35.3 19.5 11.3 NR
GM 50 mg  
q4 wk + MTX
59.6* 37.1* 20.2* NR
GM 100 mg  
q4 wk + MTX
59.6* 32.6* 14.6* NR
emery et al19  
GO-BeFORe
24 wk Placebo + MTX 49.4 29.4 15.6 28.1
GM 100 mg  
q4 wk + placebo
51.6 32.7 13.8 25.2
GM 50 mg q4  
wk + MTX
61.6* 40.3* 23.9 38.4*
GM 100 mg  
q4 wk + MTX
61.6* 36.5 18.2 37.7
Smolen et al20  
GO-AFTeR
24 wk 14 wk results
Placebo + MTX 18 6 2 1
GM 50 mg  
q4 wk + DMARD
35* 16* 10* 13*
GM 100 mg  
q4 wk + DMARD
38* 20* 9* 12*
24 wk results
Placebo + MTX 17 5 3 3
GM 50 mg 
q4 wk + DMARD
34* 18* 12* 10*
GM 100 mg  
q4 wk + DMARD
44* 20* 10* 16*
Kremer et al12 48 wk 14 wk results
Placebo + MTX 27.9 13.2 4.7 10.1
(Continued)Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Table 2 (Continued)
Reference Duration Treatment ACR20 
(%)
ACR50 
(%)
ACR70  
(%)
DAS28-CRP 
remission (%)
GM + placebo  
combined
44.0* 16 4.3 15.2
GM + MTX  
combined
53.3* 21.4 6.2 18.3*
24 wk results
Placebo + MTX 24.8 9.3 3.1 7.0
GM + placebo  
combined
26.1 10.1 4.7 8.6
GM + MTX  
combined
43.6* 21.8* 7.0 18.7*
Note: *P , 0.05 vs placebo.
Abbreviations: ACR, American College of Rheumatology 20/50/70% response criteria; DAS28, disease activity score employing 28-joint count; CRP, C-reactive protein; 
GM, golimumab; MTX, methotrexate; GO-FORwARD, GOlimumab FOR subjects with Active RA Despite methotrexate; NR, not reported; GO-BeFORe, GOlimumab 
Before employing MTX as the First-line Option in the treatment of Rheumatoid arthritis early onset; GO-AFTeR, Golimumab in patients with active rheumatoid arthritis 
after treatment with tumor necrosis factor-α inhibitors; DMARD, disease-modifying antirheumatic drug.
with CRP , 2.6) compared with 5.7% in the placebo group 
(P = 0.009). Although all GM dose regimens had   significantly 
greater proportion of patients achieving an ACR50 response 
at week 16 compared with placebo, the response was not in a 
dose-dependent manner. On the other hand, when individual 
doses of GM compared with the placebo group for all other 
secondary end points (other than ACR50), different doses of 
GM for different end points proved to be superior (Table 2). In 
other words, none of the studied doses of GM was shown to 
be superior compared with each other. However, the observed 
lack of dose-response relationship in this study might be due 
to relatively small number of patients in each dose group.
At 20-weeks follow-up, patients in the placebo group 
started open-label treatment with IV infliximab at 3 mg/kg 
followed by maintenance therapy every 8 weeks through week 
44. Unfortunately, data regarding head-to-head comparison 
of GM groups with infliximab group are not available. After 
week 16, although patients in GM groups continued to receive 
their assigned dose (50 or 100 mg), their dosing frequency 
was changed from every 2 weeks to every 4 weeks for all 
4 treatment arms. Although specific percentages were not 
provided, these patients maintained their ACR responses 
through week 52 despite less frequent dosing.
Overall, this study provided evidence that GM was supe-
rior to placebo as add-on MTX in inadequate responders 
with no clear advantage of more frequent (every 2 weeks) 
administration.
Phase 3 studies
The efficacy of GM was investigated in four phase 3 trials con-
ducted among different RA populations: the GO-FORWARD 
(GOlimumab FOR subjects With Active RA Despite metho-
trexate) study enrolled patients currently on MTX,18,19 the 
GO-BEFORE (GOlimumab Before Employing MTX as the 
First-line Option in the treatment of Rheumatoid arthritis 
Early onset) study included patients who were MTX naïve,19 
and the GO-AFTER (GOlimumab After Former anti-TNF-α 
Therapy Evaluated in RA) trial examined patients previ-
ously treated with TNF-α inhibitors.20 Although the most 
recent study was similar to GO-FORWARD as investigating 
the safety and tolerability of GM in patients with active RA 
that was not adequately controlled with MTX, this study 
was performed to support the use of or to determine the 
optimal dosage for maximal safety and effectiveness of 
GM when administered intravenously.12
The GO-FORWARD trial,18 a 1-year, double-blind, 
placebo-controlled phase 3 study, enrolled 444 patients who 
had inadequate response to MTX, was designed to demon-
strate 2 coprimary efficacy end points: ACR20 at week 14 and 
improvement in health assessment questionnaire disability 
index (HAQ-DI) at week 24 (Table 1). Twenty-four week 
results of this study that include the primary end points 
have been published. Keystone and colleagues defined inad-
equate response to MTX as patients with RA who had been 
receiving MTX for at least 3 months with a stable dose of 
15–25 mg/wk for the last 4 weeks, had active disease manifest 
by at least 4 joints that were swollen and 4 joints that were 
tender at the time of enrollment, and 2 of the following: CRP 
level $ 1.5 mg/dL, ESR $ 28 mm/h, morning stiffness of $30 
minutes, bone erosion seen on x-ray or magnetic resonance 
imaging, or anti-cyclic citrillinated peptide (CCP) antibody 
positive or rheumatoid factor (RF) positive. Although the use Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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of stable doses of NSAIDs and corticosteroids (,10 mg/d of 
prednisone or equivalent) were allowed, patients were asked 
to discontinue the use of any DMARDs within 4 weeks of 
study enrollment or TNF-α inhibitor therapy at any time. 
Patients were randomized to treatment with placebo plus 
MTX, GM 100 mg plus placebo, and GM 50 mg or 100 mg 
every 4 weeks plus MTX. At week 16, patients who had less 
than 20% improvement in tender and swollen joint counts had 
their doses adjusted in a   double-blind manner, except for the 
GM 100 mg plus MTX group.
At randomization, patients in this study had shorter dis-
ease duration (range of median 4.5–6.7 years), fewer tender 
(range of median 21–26) and swollen joints (range of median 
11–13), and lower disease activity (DAS28 CRP, range of 
median 4.8–5.1) as compared with those in previous studies 
of biological agents in patients with active RA despite MTX 
treatment. Such a difference might be individual or combined 
result of either less restrictive entry criteria in this study, or 
overall reduction in the disease activity of patients seen in 
daily practice, or increased tendency to treat RA with biologi-
cal agents early in disease course. The median weekly dose of 
MTX was 15 mg in all of the study arms, and approximately 
half of the patients had been using MTX for at least 3 years 
before the enrollment.
At week 14, despite a higher than expected placebo effect, 
both patients in the GM 50 mg plus MTX and patients in 
GM 100 mg plus MTX achieved a higher ACR20 response 
rates than patients receiving placebo plus MTX (55.1%, 
56.2% vs 33.1%, P = 0.001 and P , 0.001, respectively). No 
significant difference was detected with respect to ACR20 
responses between patients receiving MTX (33.1%) or GM 
(44.4%) as monotherapy (P = 0.059). The results were found 
to show a quite similar pattern for the coprimary end point 
of change in HAQ-DI at week 24, as patients receiving 
combination therapy (both of the dosing regimens) exhibited 
higher improvement than did patients who received MTX or 
adalimumab monotherapy (Table 2). The outcomes for the 
secondary end points including ACR50/70, DAS28 remis-
sion, and HAQ-DI at week 14, and ACR20/50/70 and DAS28 
remission at week 24 were consistent with the primary 
analysis and disclosed similar superiority of combination 
therapy (Table 2).
In conclusion, the phase 3 GO-FORWARD study 
confirmed and extended the findings of a phase 2 study by 
demonstrating that GM, with background MTX, is more 
effective than the MTX monotherapy in reducing the signs 
and symptoms of RA and improving physical function. GM 
monotherapy, however, was not found to be superior to MTX 
monotherapy in this group of patients with RA, similar to all 
other biologic trials. In addition, no apparent advantage of 
using higher dose (100 mg) of GM was shown compared with 
lower dose (50 mg) when used in combination with MTX. 
The 1-year results of the GO-FORWARD trial has recently 
been published and indicate that the response rates achieved 
at week 24 by patients who received the combination of GM 
and MTX were sustained to week 52. The combination of GM 
and MTX was more effective than either GM or MTX alone. 
Furthermore, there was no difference in efficacy of the 50 or 
100 mg dose of GM when used in combination with MTX 
(ACR20 response; 64% vs 58%, respectively).21
The GO-BEFORE trial is a double-blind, placebo-controlled, 
multicenter trial investigating the efficacy of GM in RA. It was 
designed to last 52 weeks with an open-label extension of 5 
years, whereas only the results at the 24 week are currently avail-
able.19 This study evaluated 637 patients who had early disease 
and were MTX naïve, with the median duration of RA ranging 
from 1 to 1.8 years across the study groups (Table 1).
Patients were randomized to treatment with placebo plus 
MTX (group 1), GM 100 mg plus placebo (group 2), GM 
50 mg plus MTX (group 3), and GM 100 mg plus MTX 
(group 4). GM injections were administered every 4 weeks 
and the average dose of MTX was 20 mg/wk. Although 
the study reported to have 2 coprimary end points: ACR50 
response at week 24 and a change from baseline in the 
modified Sharp/van der Heijde score at week 52, recent 
update in the clinical trials database stated that radiologic 
outcome is no longer the outcome (neither primary nor 
secondary) of this study.
At week 24, ACR50 responses were found to be 
similar between the combined group (group 3 and 4) and 
group 1 according to the prespecified intention to treat (ITT) 
analysis (38.4% vs 29.4%, respectively, P = 0.053), but when 
post hoc modified ITT analysis (excluding 3 randomized but 
untreated patients) was conducted, the difference between the 
groups became significant (38.5% vs 29.4%, respectively, 
P = 0.049). Using the same post hoc analysis, proportion of 
patients achieving ACR50 responses in GM 50 mg plus MTX 
group was found to be higher than those of patients receiving 
MTX monotherapy (40.5% vs 29.4%, respectively, P = 0.038), 
whereas no such difference was detected for patients in 
group 4 (GM 100 mg plus MTX; 36.5%, P = 0.177) (Table 2). 
GM 100 mg without MTX was found to be noninferior sta-
tistically to MTX monotherapy for ACR50 response at week 
24 (33.1% vs 29.4%, respectively). When examining the 
ACR20 responses at week 24, there was a clear response 
both in group 3 (GM 50 mg plus MTX) and group 4 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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(GM 100 mg plus MTX) with 61.6% improvement in each 
compared with 49.4% in MTX plus placebo group (P = 0.028 
for both). Furthermore, such a response in ACR20 for both 
doses of GM combined with MTX became significant as 
early as week 4 of the study. With regard to other measures 
of this study including ACR90, ACR-N, and DAS28 CRP 
remission, GM 50 mg plus MTX group was shown to be 
superior to MTX monotherapy, whereas no such advantage 
was shown for GM 100 mg plus MTX group.
Overall study results showed that subcutaneously admin-
istered GM with MTX is more effective than MTX mono-
therapy in patients who had not received MTX previously. In 
this study, as similar to the results of GO-FORWARD trial 
which was performed in MTX nonresponders, the regimen 
of GM 100 mg plus MTX did not appear to provide a greater 
efficacy than the regimen of GM 50 mg plus MTX.
The GO-AFTER trial is a double-blind,   placebo-controlled, 
multicenter trial investigating the clinical question of whether 
GM is safe and effective treatment for patients with active 
RA previously treated with at least 1 anti-TNF-α agent.20 
The randomized, double-blind component of the trial was 
designed to last 52 weeks for which the results are available 
for 24 weeks, whereas the open extension part (4 years) is 
still ongoing. To be eligible, patients had to have active dis-
ease ($4 swollen and $4 tender joints), should be treated 
with at least 1 dose of anti-TNF-α agent, and should have 
discontinued this agent (for any reason) at least 8–12 weeks 
before the study entry. Concomitant therapy with MTX, sul-
fasalazine and/or hydroxychloroquine, was permitted if the 
patient was on a stable dose for at least 4 weeks before the first 
administration of the study agent. A total of 461 patients were 
randomized to treatment with placebo and GM 50 or 100 mg 
SC every 4 weeks. Patients with ,20% improvement in 
swollen/tender joint counts in placebo or GM 50-mg groups 
could enter early escape and received double-blinded rescue 
therapy. The median disease duration (.8 years) among the 
recruited patients is longer than the previous studies of GM 
(Table 1). The disease activity is considerably high (DAS28 
ESR . 6), whereas more than 60% of the participants had 
been treated with MTX (dose not reported). Reasons for the 
discontinuation of previous anti-TNF-α agents are lack of 
effectiveness (58%) and intolerance or accessibility problems 
(53%). The efficacy of GM was evaluated at week 14, based 
on the ACR20 response (primary end point), which showed 
that more patients on each of the GM doses (35% for 50 mg 
and 38% for 100 mg) achieved this response than did those 
on placebo (18%) (0.0006 and 0.0001, respectively). There 
is no difference between the GM doses of 50 mg and 100 mg 
with regard to ACR20 responses. For weeks 14 and 24, 
  significantly more patients in each of the GM-treated groups 
achieved ACR50, ACR70, and DAS28 remission (Table 2). 
At week 14, the difference between the proportion of patients 
achieving ACR20 on combined GM and placebo groups was 
higher among patients receiving concomitant DMARDs, had 
previously received less than 3 anti-TNF-α agents, and had 
discontinued the previous anti-TNF-α agent due to lack of 
efficacy. This study provided evidence that GM can be used 
effectively as an anti-TNF-α agent in patients with RA who 
have had inadequate responses to other TNF-α inhibitors. 
Although proportion of patients achieving ACR20 response 
was lower in this study as compared with previous studies 
with GM (GO-FORWARD and GO-BEFORE), this findings 
are compatible with the observational studies suggesting 
that the probability of response decreases with an increased 
number of previous DMARDS and anti-TNF-α agents.
Although the pharmacokinetics and safety of IV GM 
administration were studied in a phase 1 trial in patients with 
RA,10 the only phase 3 study evaluating the use of IV route 
was recently published.12 The goal of this multicenter, ran-
domized, double-blind, placebo-controlled, 48-week study 
was to assess the efficacy and safety of IV administration 
of GM (with and without MTX) in patients with active RA 
despite concurrent MTX therapy. The study evaluated 643 
patients who met almost the same selection criteria as in 
the trial of SC GM in another MTX-inadequate responder 
population. The only difference between this trial and the 
previous trial was the inclusion of those patients with previ-
ous anti-TNF therapy. Patients were randomized (1:1:1:1:1) 
to receive placebo plus MTX, GM 2 mg/kg with or without 
MTX, or GM 4 mg/kg with or without MTX. IV infusions 
of study agent were administered over 30 minutes at week 
0 and every 12 weeks thereafter. Baseline demographic and 
clinical characteristics were similar across treatment groups 
and were similar to those observed in the GO-FORWARD 
trial.18 At randomization, the mean disease duration was 
more than 7 years, with medians of 23 tender and 13 swollen 
joints. At study entry, half of the patients had been receiving 
MTX therapy for 3 or more years (overall median MTX dose 
was 15 mg/wk), and 80% of them were receiving corticos-
teroids, whereas approximately 60% of them had a history 
of DMARD and 5% had a history of anti-TNF use. The 
primary outcome measure was the percentages of patients 
who achieved ACR50 response at week 14. Secondary 
end points were the percentages of patients who achieved 
ACR50 response at week 24, ACR20 response at week 14, 
and DAS28 response using CRP at week 14 (Table 1).Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The study did not meet its primary end point at week 14, 
as showing no difference in the proportion of patients achieving 
ACR50 response between the combined GM (2 and 4 mg/kg) 
plus MTX group (21.4%) and in the group that received pla-
cebo plus MTX (13.2%) (P = 0.051).   However, by week 24, 
significantly more GM plus MTX-treated patients achieved 
an ACR50 response compared with placebo plus MTX (22% 
vs 9%, P = 0.002). There was no difference in the ACR50 
response rates at any time point for GM monotherapy com-
pared with placebo plus MTX.
ACR20 responses at week 14 in patients treated with GM 
2 and 4 mg/kg plus MTX were 55 and 51.6%, respectively, vs 
27.9% in patients treated with placebo plus MTX (P , 0.001, 
each). Although similar findings for ACR20 response were 
observed for patients treated with GM monotherapy at week 
14, the superiority of GM treatment as compared with placebo 
plus MTX was sustained only among patients receiving GM 
plus MTX through week 24 (Table 2). There were no signifi-
cant differences in ACR70 response rates between patients 
who received GM (both of the doses, either as monotherapy 
or combined with MTX ) compared with those who received 
placebo plus MTX. Correlated with the other clinical out-
comes, at week 14, 18.3% of patients in the combined GM plus 
MTX groups and 25% in the GM 4 mg/kg plus MTX groups 
achieved DAS28-CRP remission compared with 10.1% in 
the placebo plus MTX group (P = 0.036 and P = 0.002, 
respectively). Similar trends for DAS28-CRP remission were 
observed at week 24 for patients in the GM plus MTX groups, 
and as similar to the results of the week 14, no significant dif-
ference was detected in the proportion of patients achieving 
remission in both doses of GM monotherapy group vs the 
placebo plus MTX group (Table 2).
Despite the primary study end point (ACR50 response 
at week 14 was not achieved), these findings suggested that 
IV GM, when used in combination with MTX, may improve 
the symptoms and disease activity in patients with RA with 
incomplete response to MTX monotherapy. IV   administration 
of GM offers the advantage of less frequent dosing (every 12 
weeks) compared with SC form (every 4 weeks). However, 
considering the lack of satisfactory ACR50 response at week 
14, further studies investigating different dosing strategy for 
IV form may be needed.
PsA
The approval of GM for the treatment of PsA was based 
on the results found in 1 pilot clinical study evaluating the 
safety and efficacy of GM. Golimumab – A Randomized 
Evaluation of Safety and Efficacy in Subjects with Psoriatic 
Arthritis Using a Human Anti-TNF Monoclonal Antibody 
(GO-REVEAL) is a phase 3, multicenter, randomized, dou-
ble-blind, placebo-controlled trial involving 405 patients with 
active PsA and a history of inadequate response to NSAIDs 
or DMARDs.13 Patients were considered active if they had 
$3 swollen and $3 tender joints in addition to at least 1 
psoriasis plaque measuring $2 cm in diameter. Stable doses 
of MTX, NSAIDs, and corticosteroids (prednisone 10 mg/d) 
were allowed. Patients were randomized to receive SC injec-
tions of placebo, GM 50 mg, or GM 100 mg every 4 weeks for 
24 weeks. At week 16, patients with ,10% improvement from 
baseline in both the swollen and tender joint counts entered 
early escape. Mean age of the patients was 47 years, and 60% 
were men. Almost half of the patients had polyarticular type 
PsA with a mean disease duration of more than 8 years. At 
study entry, half of the patients had been receiving MTX 
therapy with a median MTX dose of 15 mg/wk, and 20% of 
them were receiving corticosteroids, whereas approximately 
75% of them being treated with NSAIDs.
The primary end point was the proportion of patients 
meeting the ACR20 response at week 14. Major secondary 
end points included the ACR20 response at week 24, achieve-
ment of at least 75% improvement in the psoriasis area and 
severity index (PASI),22 at week 14 in the subset of patients 
in whom at least 3% of the body surface area was affected 
by psoriasis at baseline, and HAQ scores at week 24.
At week 14, 48% of all patients receiving GM, 51% 
of patients receiving 50-mg GM, and 45% of patients 
  receiving 100-mg GM achieved an ACR20 response (the 
primary end point) compared with 9% of patients receiving 
placebo (P , 0.001 for all comparisons). By week 24, 52% 
of patients in the GM 50-mg group and 61% of patients in 
the GM 100-mg group achieved an ACR20 response (major 
secondary end point) compared with 12% of patients in the 
placebo group (P , 0.001 for both comparisons). Indeed, 
consistent with the primary outcome, patients who received 
GM (both doses) showed significantly greater ACR50, 
ACR70, change in the DAS28-CRP, and Psoriatic Arthritis 
Response Criteria (PsARC) response,23 at all measured time 
points as compared with those on placebo.
This study also demonstrated the clinical efficacy of GM in 
improving the skin and nail lesions of psoriasis. Among those 
with evaluable skin disease, 40% of the GM 50-mg group and 
58% of the GM 100-mg group achieved PASI 75 compared 
with 3% of the placebo group at week 14 (P , 0.001 for each 
dose). Likewise, both at weeks 14 and 24, the nail psoriasis Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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severity index24 showed significant improvement from baseline 
in each GM-dose group vs placebo.
Disability at 24 weeks, as measured by patient responses 
to the HAQ scores, showed significantly more improvement 
from baseline in 50-mg- and 100-mg-doses GM group 
(0.33 ± 0.55 and 0.39 ± 0.50, respectively) than in the placebo 
group (−0.01 ± 0.49) (P , 0.001 for both comparisons).
In addition to the beneficial effects observed in arthritis 
measures, the median percentage of improvement in the 
dactylitis severity score was significantly higher at both time 
points with 100-mg dose of GM. With respect to enthesitis, 
those patients in both of the GM arms similarly experienced 
greater clinical improvement (PsA modified Maastricht 
Ankylosing Spondylitis Enthesitis Score [MASES]) over 
those receiving placebo, a response that increased over 
time.
Finally, results of GO-REVEAL trial imply that GM is effec-
tive not only for patients with PsA but also for those patients hav-
ing skin disease, psoriatic nail disease, enthesitis, and dactylitis. It 
is of note that differences between the 50-mg and 100-mg doses 
of GM were modest, whereas some evidence suggests that skin 
disease may respond better to the higher doses of GM. This study 
also illustrated that concomitant use of MTX did not result in 
additional improvement in either joint or skin disease.
AS
The pivotal study to prove the efficacy and safety of GM in 
AS was the randomized, double-blind, placebo-controlled, 
multicenter GO-RAISE trial conducted over 24-week 
  period.14 The inclusion criteria for this trial was similar to 
the previous trials of biological agents in AS and comprised 
fulfillment of modified New York criteria for definite AS,25 
active disease (as indicated by a Bath AS disease activity 
index [BASDAI] score . 4), pain score of .4 on visual 
analogue scale (0–10), and an inadequate response to 
NSAIDs and DMARDs. Patients were allowed to continue 
stable doses of concomitant MTX, sulfasalazine, hydroxy-
chloroquine, low-dose corticosteroids, and/or NSAIDs, 
but the use of other DMARDs is prohibited. Patients with 
complete spinal ankylosis were also excluded. A total of 
356 patients were randomly assigned to placebo, GM 50 
mg, or GM 100 mg, given SC every 4 weeks. There was 
an “early escape” at week 16 in the study whereby patients 
who meet criteria for having little improvement in their AS 
symptoms were switched to GM if they were on placebo or 
have the GM dose increased if they were originally assigned 
to the GM 50-mg group.
Baseline characteristics of patients resembled the previ-
ous studies conducted among patients with AS with different 
agents: they were predominantly men (70%), white (.90%), 
with a median age of 40 years and median disease duration 
of approximately 7 years.
The primary end point was the proportion of patients who 
achieved at least 20% improvement in the ASsessment in AS 
International Working Group criteria (ASAS20) at week 14.26 
Secondary end points included ASAS 40% improvement 
(ASAS40),26 ASAS partial remission, and 20% improvement 
in 5 of 6 ASAS domains (ASAS5/6).27
After week 14, 59.4% of patients in the 50-mg group 
and 60% of patients in the 100-mg group were ASAS20 
responders compared with 21.8% of patients in the placebo 
group (P , 0.001, for each). Of the patients who received 
GM, 43.5% and 54.3% of patients achieved an ASAS40 
response in 50-mg and 100-mg groups, respectively, at week 
24 compared with 15.4% in the placebo group (P , 0.001, 
for each). Although significantly more patients receiving GM 
(50 mg and 100 mg) were reported to achieve an ASAS20, 
ASAS5/6 response, and partial remission at week 24 as 
similar to those observed at week 14, no numerical data are 
available about these end points. Consistent with the other 
measures, the BASDAI-50 response (.50% improvement) 
was seen in half of the GM-treated patients compared with 
15% in the placebo arm (P , 0.001, for each). Symptom 
benefit was seen as early as 4 weeks after treatment com-
mencement and sustained throughout week 24.
Taken together, all the data of this trial provide evidence 
of the short-term clinical efficacy of both the doses of GM, 
administered SC every 4 weeks in patients with AS refractory 
to conventional treatment. Furthermore, no clear difference 
in efficacy was evident between the 50-mg and 100-mg-dose 
groups through week 24.
Safety
Overall, data obtained from the clinical trials performed in 
various settings (RA, PsA, AS) suggest that GM appears 
to be safe and well tolerated. However, it should be kept 
in mind that none of the studies of GM were designed with 
safety as primary outcome; therefore, definitive conclusions 
about the safety cannot be drawn. Furthermore, all of the 
trials for which the safety data are available are short dura-
tion studies.
The incidence of serious (2%–7%) and nonserious 
(60%–80%) adverse events in the GM-treated groups were 
similar to those observed in placebo groups with nausea, Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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headache, and injection site reaction reported most often. There 
was no notable relationship between overall adverse event 
rates and GM dose. The proportion of patients who discontin-
ued treatment because of adverse reactions in the controlled 
phase 3 trials through week 16 in RA, PsA, and AS was 2% 
for GM-treated patients and 3% for placebo-treated patients. 
Injection site reactions were observed in a rate ranging from 
5% to 25%. They were primarily mild in intensity and consisted 
most often of injection site erythema, bruising, or warmth. 
No patient discontinued treatment because of an injection site 
reaction.12–14,18–20 In the only study evaluating IV use of GM, the 
incidence of infusion reactions among all GM-treated patients 
was 4% compared with 5% for placebo plus MTX.12
Anti-TNF agents may affect host defenses against 
infections since TNF is involved in modulating this 
process. In clinical trials of GM, infections are one of 
the most commonly reported adverse events (30%). In 
general, the safety profile of GM in patients with RA 
appears comparable to that of other disease settings (PsA, 
AS). However, the frequency of infections, in general, was 
reported to be higher in patients with AS receiving GM 
(45%) compared with those of the patients with RA.14 The 
overall frequency of infections, in general, and nonupper 
respiratory tract infections in particular were similar in 
patients treated with GM or placebo. Nonetheless, upper 
respiratory tract infections were slightly more common 
in patients treated with GM (12%) than placebo (7%). In 
different trials, including the trials performed in AS and 
PsA, excepting a minor increase among patients receiving 
combination of MTX and high dose of GM (4%–5%), there 
were no data indicating a significantly higher frequency 
of serious infections as compared with placebo (1%–4% 
GM groups vs 0.7%–3% placebo). Among the patients 
treated with GM, serious infections that have occurred 
included pneumonia, gastroenteritis, otitis media, urinary 
tract infection, and sepsis.
Tuberculosis (TB) is the most frequent opportunistic 
infection that has been reported with TNF-α inhibitors. 
Indeed, TNF-α plays a role in the host defense against 
Mycobacterium tuberculosis and notably in granuloma 
formation and in containment of latent disease.28 Consider-
ing the previous experience with other TNF-α inhibitors, 
all patients screened for clinical trials of GM were also 
screened for TB. In all but 2 studies, patients with posi-
tive results for TB screening were allowed to participate 
but had to start prophylaxis for latent TB. Approximately, 
10%–20% of the patients in these 5 studies had latent TB 
at screening and entered the study receiving prophylaxis. 
Overall, TB developed in 3 patients. In GO-BEFORE 
study, 1 patient was diagnosed TB of the spine after 
receiving the third dose of GM. A review of the patient’s 
report indicated that the spinal lesion was present before 
the study entry, whereas no data are available about the 
patient’s prophylaxis status.19 The other 2 reported cases 
were from the study investigating IV administration of 
GM and occurred between weeks 24 and 48 in patients 
who initially tested negative for TB at screening.12 At 
this time, it is reasonable to assume from the existing 
data that the development of active TB is a class effect 
that may be expected with the use of any TNF-α inhibi-
tors including GM. Only 1 opportunistic infection (liver 
histoplasmosis) other than TB has been reported with the 
use of GM thus far.
Antibodies to GM were detected in a low percentage of 
patients (approximately 5% and 7%, respectively) follow-
ing both IV and SC administration. The antibody titers were 
generally low, and no antibody positive patients exhibited an 
infusion site reaction or significant lack of efficacy.
In general, GM treatment appeared unassociated with 
onset of malignancies. However, relatively small number of 
patients in the controlled trials of GM makes it difficult to 
interpret differences in the percentage of infrequent events, 
such as cancer and death.
The safety profile of GM does not bear surprises com-
pared with other TNF-α inhibitors, although conclusive 
safety data on this compound will have to await postmarket-
ing strategies. As with most of the biologic trials, the way 
safe data were reported leaves a lot to be desired. No data 
regarding time to event or what happened after the serious 
events were provided. Use of patients years and means of 
event rates are inadequate in any trial for reporting safety 
data.29
Although concluding statements are still difficult about 
the safety of GM because of the paucity of data available, 
the following 7 types of adverse events seem to be of special 
concern for patients treated with GM therapy considering the 
experience with other TNF-α inhibitors:
•	 Infections including sepsis and TB
•	 Malignancies such as lymphoma
•	 Hematological disorders such as anemia and pancytopenia
•	 Demyelinating disorders and neuropathy
•	 Onset and worsening of congestive heart failure
•	 Occurrence of autoantibodies and autoimmunity
•	 Injection/infusion and hypersensitivity reactions
It is possible that GM might differ from other TNF-α 
inhibitors in terms of adverse reactions. It is, however, pru-Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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dent to keep the afore-mentioned possible adverse events in 
mind when treating patients with GM.
Conclusion
The various ongoing trials for GM have yielded promising 
results in terms of efficacy and safety in MTX-naïve and 
MTX-resistant patients with RA, as well as in patients 
with RA who were previously treated with other anti-TNF 
agents. In addition, the efficacy of GM in PsA and AS 
has also been demonstrated. The real safety informa-
tion will only be available once the drug has been used 
in many more patients, who frequently have comorbid 
conditions. Some of this data, if collected and analyzed 
correctly, may be available from the currently active 
biologic registries.
Although the efficacy of GM was not tested against 
other TNF-α inhibitors in controlled trials, its efficacy 
is unlikely to be superior compared with other TNF-α 
inhibitors available in the market. With respect to molecular 
structure, it is most similar to adalimumab, but it requires 
less frequent administration and is labeled for patient self-
administration. For all indications, the approved GM dosage 
is 50 mg administered by SC injection once a month. Thus, 
the appeal of GM in an already crowded arena is primarily 
being an option to patients desiring less frequent injections. 
Though more time is needed to appreciate any long-term 
consequences, till date GM exhibits a favorable risk-benefit 
profile, which is quite similar to the other TNF-α inhibitors 
available in the market.
Although GM therapy has been investigated in controlled 
trials over 6 months, additional trials are needed to determine 
long-term safety of this agent and whether the clinical ben-
efits of GM found in the clinical trials reviewed in this study 
would be sustained over time.
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